Private Equity Natixis serves as Executive at EYEGATE PHARMACEUTICALS INC, where they oversee executive responsibilities. Since joining the company, Private Equity Natixis has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Feb 19, 2015 involved exercising options for 97,641 shares valued at $410.1K.
Private Equity Natixis currently holds 674,205 shares of EYEGATE PHARMACEUTICALS INC (EYEG), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Private Equity Natixis has been a net neutral trader of EYEG stock. They have purchased $0 and sold $0 worth of shares.
Private Equity Natixis's most recent insider trade was on Feb 19, 2015, when they sold 97,641 shares at $4.20 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |